ES8201827A1 - Procedimiento para pasteurizar una composicion que contiene una proteina termicamente sensible y terapeuticamente activa - Google Patents

Procedimiento para pasteurizar una composicion que contiene una proteina termicamente sensible y terapeuticamente activa

Info

Publication number
ES8201827A1
ES8201827A1 ES500121A ES500121A ES8201827A1 ES 8201827 A1 ES8201827 A1 ES 8201827A1 ES 500121 A ES500121 A ES 500121A ES 500121 A ES500121 A ES 500121A ES 8201827 A1 ES8201827 A1 ES 8201827A1
Authority
ES
Spain
Prior art keywords
pasteurized
therapeutically active
active protein
protein compositions
pasteurization
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES500121A
Other languages
English (en)
Other versions
ES500121A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Corp
Original Assignee
Cutter Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26825565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES8201827(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cutter Laboratories Inc filed Critical Cutter Laboratories Inc
Publication of ES8201827A1 publication Critical patent/ES8201827A1/es
Publication of ES500121A0 publication Critical patent/ES500121A0/es
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/363—Fibrinogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/484—Plasmin (3.4.21.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4853—Kallikrein (3.4.21.34 or 3.4.21.35)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/04—Heat
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6445—Kallikreins (3.4.21.34; 3.4.21.35)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

PROCEDIMIENTO PARA PASTEURIZAR UNA COMPOSICION PROTEINICA QUE CONTIENE PROTEINAS DERIVADAS DE PLASMA SANGUINEO VENOSO O PLASMA PLACENTAL. LA COMPOSICION PROTEINICA, QUE INCLUYE PLASMA SANGUINEO, PLASMA SANGUINEO PARCIALMENTE FRACCIONADO, FRACCIONES INDUVIDUALES DE PLASMA SANGUINEO O PROTEINAS INDIVIDUALES DE PLASMA SANGUINEO, SE SUSPENDE O DISULVE EN UNA SOLUCION ACUOSA QUE CONTIENE AL MENOS 30 POR 100 HASTA SATURACION DE UN POLIOL CON UN PESO MOLECULAR INFERIOR A 5.000, COMO MONO-DI- Y TRISA-CARIDOS. SE CALIENTA LA MEZCLA A UNA TEMPERATURA ENTRE 60-70C DURANTE DIEZ HORAS APROXIMADAMENTE Y CON UN PH ENTRE 6 Y 7,5, PARA PASTEURIZARLA INACTIVANDO EL VIRUS DE HEPATITIS.
ES500121A 1980-03-05 1981-03-05 Procedimiento para pasteurizar una composicion que contiene una proteina termicamente sensible y terapeuticamente activa Granted ES500121A0 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12735180A 1980-03-05 1980-03-05
US20250880A 1980-10-31 1980-10-31

Publications (2)

Publication Number Publication Date
ES8201827A1 true ES8201827A1 (es) 1982-01-01
ES500121A0 ES500121A0 (es) 1982-01-01

Family

ID=26825565

Family Applications (1)

Application Number Title Priority Date Filing Date
ES500121A Granted ES500121A0 (es) 1980-03-05 1981-03-05 Procedimiento para pasteurizar una composicion que contiene una proteina termicamente sensible y terapeuticamente activa

Country Status (7)

Country Link
EP (1) EP0035204B2 (es)
JP (1) JPH0611702B2 (es)
CA (1) CA1187410A (es)
DE (1) DE3176491D1 (es)
DK (1) DK156698C (es)
ES (1) ES500121A0 (es)
MX (1) MX6967E (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200032B2 (en) 2012-03-20 2015-12-01 Grifols, S.A. Process for obtaining an IgG composition through heat treatment

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481189A (en) * 1982-04-14 1984-11-06 New York Blood Center Inc. Process for preparing sterilized plasma and plasma derivatives
US4439358A (en) * 1982-06-17 1984-03-27 Miles Laboratories, Inc. Method of preparing alpha-1-proteinase inhibitor
US4412990A (en) * 1982-07-02 1983-11-01 Cutter Laboratories, Inc. Composition having enhanced opsonic activity
US4434093A (en) * 1982-07-26 1984-02-28 Ortho Diagnostic Systems Inc. Methods for preparation of HBs Ag free gamma globulins
DE3228502A1 (de) * 1982-07-30 1984-02-02 Behringwerke Ag, 3550 Marburg Verfahren zur herstellung des c1-inaktivators und seine verwendung
DE3230849A1 (de) * 1982-08-19 1984-02-23 Behringwerke Ag, 3550 Marburg Pasteurisiertes human-fibrinogen (hf) und verfahren zu dessen herstellung
DE3237512A1 (de) * 1982-10-09 1984-04-12 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von antihaemophilem kryopraezipitat (ahk) und danach hergestelltes antihaemophiles kryopraezipitat
JPS59134730A (ja) * 1983-01-20 1984-08-02 Green Cross Corp:The 血液凝固第８因子の加熱処理法
DE3467706D1 (en) * 1983-04-28 1988-01-07 Armour Pharma Pharmaceutical preparation containing purified fibronectin
CA1213827A (en) * 1983-04-29 1986-11-12 Ricardo H. Landaburu Process for pasteurizing fibronectin
EP0124506B1 (de) * 1983-05-02 1988-08-17 IMMUNO Aktiengesellschaft für chemisch-medizinische Produkte Verfahren zur Inaktivierung von vermehrungsfähigen Krankheitserregern
DE3330770A1 (de) * 1983-08-26 1985-03-14 Behringwerke Ag, 3550 Marburg Verfahren zur pasteurisierung von humanplasma
JPS6094917A (ja) * 1983-10-28 1985-05-28 Green Cross Corp:The Ｂ型肝炎感染予防用ワクチンの製造方法
JPS6098988A (ja) * 1983-11-01 1985-06-01 Chemo Sero Therapeut Res Inst Ｌｐｆ−ｈａの精製法
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
JPS61501510A (ja) * 1984-03-23 1986-07-24 バクスタ−、トラベノ−ル、ラボラトリ−ズ、インコ−ポレイテッド ビ−ルスリスクを減らしたヘモグロビンおよびその製造方法
DE3426903A1 (de) * 1984-07-20 1986-01-23 Biotest Pharma GmbH, 6000 Frankfurt Eine immunglobulinpraeparation in kombination mit einer anderen pharmakologisch wirksamen praeparation zur verwendung bei der behandlung von krankheiten
JPH0669961B2 (ja) * 1984-09-25 1994-09-07 株式会社ミドリ十字 免疫グロブリンの加熱処理方法
AT390373B (de) * 1984-10-02 1990-04-25 Schwab & Co Gmbh Verfahren zur pasteurisation von plasmaproteinen bzw. von plasmaproteinfraktionen
JPS61103836A (ja) * 1984-10-24 1986-05-22 Green Cross Corp:The フイブロネクチン製剤
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
AT385658B (de) * 1985-03-28 1988-05-10 Serotherapeutisches Inst Wien Verfahren zur herstellung einer fuer die anwendung beim menschen geeigneten fibronektinloesung
JPH0825903B2 (ja) * 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
EP0225581A3 (en) * 1985-11-30 1989-05-24 Green Cross Corporation Method for the heat-treatment of immunoglobulins and immunoglobulin product
DK595285D0 (da) * 1985-12-20 1985-12-20 Nordisk Gentofte Injicerbart og varmebehandet igg-praeparat og fremgangsmaade til fremstilling af samme
DE3602688A1 (de) * 1986-01-30 1987-08-06 Behringwerke Ag Verfahren zur gewinnung und herstellung eines pasteurisierten praeparates von (alpha)(pfeil abwaerts)2(pfeil abwaerts)-antiplasmin
US4933433A (en) * 1986-01-31 1990-06-12 E. I. Du Pont De Nemours And Company Recombinant interleukin-2 composition and process for making it
US4816568A (en) * 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
JPH0725696B2 (ja) * 1986-05-29 1995-03-22 株式会社ミドリ十字 プラスミノ−ゲンの安定化方法
AT390560B (de) * 1986-05-30 1990-05-25 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
DE3621828A1 (de) * 1986-06-28 1988-01-14 Biotest Pharma Gmbh Stabilisierung eines fuer therapeutische zwecke, insbesondere beim menschen, bestimmten interleukin-2-praeparates sowie dieses praeparat enthaltende stabilisierte waessrige loesung oder feststoff
JPH07103045B2 (ja) * 1986-07-09 1995-11-08 株式会社ミドリ十字 非化学修飾γ−グロブリンの加熱処理方法
FR2610633B1 (fr) * 1987-02-05 1992-09-18 Lille Transfusion Sanguine Procede d'obtention d'un concentre d'a 1-antitrypsine a partir de plasma humain et son utilisation a titre de medicament
JP2547556B2 (ja) * 1987-02-06 1996-10-23 株式会社 ミドリ十字 ｒ−グロブリンの液状製剤
IL86417A (en) * 1987-05-22 1992-09-06 Armour Pharma Process for the inactivation of pathogens in biological or pharmaceutical material by mixing with aqueous solution containing a sugar(alcohol)and neutral salts as stabilizers
JPH01305036A (ja) * 1988-05-31 1989-12-08 Green Cross Corp:The 血漿蛋白成分の加熱処理方法および血漿蛋白成分製剤
FR2650508A1 (fr) 1989-08-01 1991-02-08 Fondation Nale Transfusion San Colle pasteurisee pour reunir des tissus humain ou animal
DE4001451A1 (de) * 1990-01-19 1991-08-01 Octapharma Ag Stabile injizierbare loesungen von faktor viii und faktor ix
FR2664165B1 (fr) 1990-07-03 1992-10-16 Lille Transfusion Sanguine Composition pour stabiliser le plasma sanguin en cours de pasteurisation.
DE4039721A1 (de) * 1990-12-13 1992-06-17 Behringwerke Ag Verfahren zur herstellung eines pasteurisierten und eisenfreien human-transferrins und seine verwendung
DE4111393A1 (de) * 1991-04-09 1992-10-15 Behringwerke Ag Stabilisierte faktor viii-praeparationen
AT402891B (de) * 1991-06-20 1997-09-25 Immuno Ag Verfahren zur herstellung eines inaktivierten blutproduktes
JP2722143B2 (ja) * 1991-09-03 1998-03-04 株式会社ミドリ十字 トリプシンインヒビター含有凍結乾燥製剤
AT399818B (de) * 1992-04-24 1995-07-25 Immuno Ag Verfahren zur herstellung einer hochgereinigten virussicheren faktor viii-präparation
CA2124690C (en) * 1992-10-02 2007-09-11 Thomas Osterberg Composition comprising coagulation factor viii formulation, process for its preparation and use of a surfactant as stabilizer
DE4237977A1 (de) * 1992-11-11 1994-05-19 Braun Melsungen Ag Pasteurisierung von Hemoglobin
AU6653094A (en) * 1992-12-16 1994-07-04 Immuno Aktiengesellschaft Process for preparing a virus-safe biological composition
JP3220539B2 (ja) * 1992-12-25 2001-10-22 日本ケミカルリサーチ株式会社 活性乳蛋白成分含有製品およびその製造法
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US6288030B1 (en) 1993-12-22 2001-09-11 Amgen Inc. Stem cell factor formulations and methods
ECSP941055A (es) * 1994-01-13 1994-11-16 Nestle Sa Composicion y procedimiento utilizado para estabilizar proteinas de huevo sujetas a tratamiento termico subsiguiente
EP0663151B1 (en) * 1994-01-13 2000-08-30 Societe Des Produits Nestle S.A. Composition and process used for stabilizing egg yolk proteins subjected to subsequent heat treatment
US6358722B1 (en) 1994-04-25 2002-03-19 Roche Vitamins, Inc. Heat tolerant phytases
US6699704B1 (en) 1994-04-25 2004-03-02 Roche Vitamins Inc. Heat tolerant phytases
US5741894A (en) * 1995-09-22 1998-04-21 Baxter International, Inc. Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form
DE19618851C1 (de) * 1996-05-10 1997-07-24 Octapharma Ag Verfahren zur Eignungsprüfung von Faktor VIII-haltigen Proteinfraktionen
US6632648B1 (en) * 1996-05-14 2003-10-14 Elan Drug Delivery Limited Methods of terminal sterilization of fibrinogen
EP0954534A1 (en) * 1996-07-18 1999-11-10 Csl Limited Pasteurization of immunoglobulin solutions
US6458556B1 (en) 1996-07-25 2002-10-01 The Institute Of Physical & Chemical Research Method for enhancing enzyme activity at elevated temperature
US6013488A (en) 1996-07-25 2000-01-11 The Institute Of Physical And Chemical Research Method for reverse transcription
TW491855B (en) * 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
CA2231948C (en) 1997-03-25 2010-05-18 F. Hoffmann-La Roche Ag Modified phytases
NZ330940A (en) 1997-07-24 2000-02-28 F Production of consensus phytases from fungal origin using computer programmes
EP0969089A1 (en) * 1998-06-29 2000-01-05 F. Hoffmann-La Roche Ag Phytase formulation
AU760737B2 (en) * 1998-06-29 2003-05-22 Dsm Ip Assets B.V. Phytase formulation
DE19856443A1 (de) * 1998-12-08 2000-06-21 Centeon Pharma Gmbh Stabilisiertes Antithrombin III-Präparat
DK1820516T3 (da) 1999-02-22 2013-10-28 Univ Connecticut Nye albuminfrie faktor VIII-præparater
BR0316563A (pt) * 2002-11-25 2005-10-04 Octapharma Ag Fração de albumina derivada de plasma exaurido de prekallikrein
US9284625B2 (en) * 2007-11-20 2016-03-15 Nalco Company Use of polyols as scale control reagents in the mining processes
MX339060B (es) 2008-11-07 2016-05-09 Baxter Int Formulaciones del factor viii.

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2897123A (en) * 1956-09-21 1959-07-28 Ortho Pharma Corp Plasminogen sterilization
US3227626A (en) * 1961-09-18 1966-01-04 Merck & Co Inc Plasminogen heat sterilization
BE629149A (es) * 1962-03-03
DE1189674B (de) * 1963-06-12 1965-03-25 Behringwerke Ag Verfahren zur Isolierung von alpha-Antitrypsin
IL30448A (en) * 1967-08-02 1972-06-28 Diagnostic Data Inc Protein metal chelate composition stabilized with saccharide,and preparation thereof
US4178368A (en) * 1971-09-30 1979-12-11 Behringwerke Aktiengesellschaft Method for the treatment of thromboembolism
US3903262A (en) * 1972-03-13 1975-09-02 Cutter Lab Pharmaceutical compositions comprising intravenously injectable modified serum globulin, its production and use
US4137307A (en) * 1973-11-15 1979-01-30 The Green Cross Corporation Process for preparing haptoglobin aqueous solution using strong anion exchanger
US4061735A (en) * 1973-11-15 1977-12-06 The Green Cross Corporation Haptoglobin in aqueous solution and process for preparing the same
JPS5322139B2 (es) * 1973-11-15 1978-07-06
US4046877A (en) * 1975-07-18 1977-09-06 Syntex (U.S.A.) Inc. Method of increasing immunologic competence
JPS51118819A (en) * 1975-04-08 1976-10-19 Green Cross Corp:The A process for preparing heat stable antitrypsin
JPS51118820A (en) * 1975-04-08 1976-10-19 Green Cross Corp:The A process for preparing heat stable macroglobulin
GB1507215A (en) * 1975-08-19 1978-04-12 Green Cross Corp Processes for producing immunoregulatory preparations
US4089944A (en) * 1975-12-22 1978-05-16 Baxter Travenol Laboratories, Inc. Rapidly solubilized AHF composition and process for preparing same
AT350726B (de) * 1976-08-30 1979-06-11 Immuno Ag Verfahren zur herstellung einer blut- gerinnungsfoerdernden praeperation aus menschlichem blutplasma
JPS5359018A (en) * 1976-11-10 1978-05-27 Green Cross Corp:The Concentrated xiii-th blood coagulating factor derived from human placentaand its preparation
JPS6015B2 (ja) * 1977-07-16 1985-01-05 株式会社新潟鐵工所 水溶性かつ熱凝固性を有する殺菌された血粉の製造方法
JPS597693B2 (ja) * 1978-01-07 1984-02-20 株式会社ミドリ十字 抗トロンビン製剤及びその製法
US4186192A (en) * 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
DE2916711A1 (de) * 1979-04-25 1980-11-06 Behringwerke Ag Blutgerinnungsfaktoren und verfahren zu ihrer herstellung

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9200032B2 (en) 2012-03-20 2015-12-01 Grifols, S.A. Process for obtaining an IgG composition through heat treatment

Also Published As

Publication number Publication date
MX6967E (es) 1987-01-09
CA1187410A (en) 1985-05-21
JPH0611702B2 (ja) 1994-02-16
EP0035204A2 (en) 1981-09-09
JPS56139422A (en) 1981-10-30
DE3176491D1 (en) 1987-11-26
DK156698C (da) 1990-02-05
ES500121A0 (es) 1982-01-01
DK156698B (da) 1989-09-25
EP0035204B2 (en) 1991-05-22
EP0035204A3 (en) 1982-11-10
DK98681A (da) 1981-09-06
EP0035204B1 (en) 1987-10-21

Similar Documents

Publication Publication Date Title
ES8201827A1 (es) Procedimiento para pasteurizar una composicion que contiene una proteina termicamente sensible y terapeuticamente activa
IT8122859A0 (it) Derivati dell'acido 2-idrossi-5-fenilazobenzoico, composizioni farmaceutiche che licontengono e procedimento per laloro preparazione.
DE3166441D1 (en) Novel antihistamines, process for their preparation and pharmaceutical compositions containing them
EP0004467A3 (en) Bis-anthracyclines, methods of making and using them, liposome compositions for administering them and methods of making such compositions
IL64885A (en) 3,20-dioxo-1,4-pregnadiene-17alpha-ol-17-aromatic heterocyclic esters,their preparation and pharmaceutical compositions containing them
DK250181A (da) Fremgangsmaade til fremstilling af vinblastinderivater
NO156373C (no) AnalogifremgangsmŸte for fremstilling av terapeutisk aktive furo-(3,4-c)-pyridinderivater.
IT8019276A0 (it) N-benzil-immidazoli come inibitori selettivi dell'enzima trombossano sintetasi, loro composizioni farmaceutiche e procedimento per la loro preparazione.
DK31784A (da) Phosphorholdige amidforbindelser, farmaceutiske kompositioner indeholdende disse, og fremgangsmaader til forbindelsernes fremstilling
DK93685D0 (da) Benzisoselenazolthioner, fremgangsmaade til fremstilling af disse forbindelser og farmaceutiske praeparater indeholdende disse forbindelser
JPS55108860A (en) Hydroxypropylltriazole*its manufacture and use as medicine
IL74734A0 (en) Substituted alpha-amino acids,their preparation and pharmaceutical compositions containing them
IT8319385A0 (it) Prodotti di cioccolato con maggiore contenuto di proteine eprocedimento per la produzione diprodotti di tipo siffatto.
DE3166084D1 (en) Tricyclic cytosine derivatives for use in pharmaceutical preparations and process for their preparation
DE3068383D1 (en) Novel sulfonamides, compositions containing them, and methods for controlling the growth of undesired vegetation using them
DE3367592D1 (en) Novel derivatives of n,n-substituted azolecarboxamide and agricultural and horticultural fungicidal or nematicidal composition containing same as active ingredients
DE3060962D1 (en) Peptides having thymopoietin-like activity, therapeutic compositions containing them, and process for their preparation
FI861329L (fi) Anvaendning av 4-(isoxazolyl)-tiazol-2-oxaminsyraderivat.
IT8023161A0 (it) Composti ad attivita' mucolitica non assimilabili, processo per laloro preparazione e composizioni terapeutiche che li comprendono come principio attivo.
IL73900A0 (en) Protection of keratinous material from insects by treatment with pyridyloxytrifluoromethane-sulfonanilides,certain such novel compounds,their preparation and compositions containing them
IL47633A (en) Compositions for the treatment of bovine mastitis containing 4-c5-nitro-furyl)-quinaldinic acid n-oxide
DE3161847D1 (en) Cyclic esters, process for their preparation and their use as parfuming and flavouring agents; parfume and flavouring compositions containing them
IT8521528A0 (it) Composizioni farmaceutiche e cosmetiche contenenti come ingrediente attivo diidrossi-1,8fenil-10 antrone-9, e procedimentodi preparazione dell'ingrediente attivo.
ES8302634A1 (es) Procedimiento de preparacion de derivados del acido metilen-2-succinamico
IT8249226A0 (it) Eventualmente sostituiti sell'anelderivati di 20,21-dinoreburnamenina lo e, procedimento ed intermedi di preparazione, applicazione come medicamenti e composizioni che li con tengono